Companies · Other
BIRMINGHAM · Other
Diligence memoA one-page analyst read on Trivela Pathway LP — recommendation, valuation, rhythm, risks.→Trivela Pathway LP looks over-valued against its niche peers and is at-risk on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Trivela Pathway LP behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
Trivela Pathway LP is one of 25008 Other companies tracked from BIRMINGHAM. By capital raised it ranks among the largest (ahead of 91% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 25008 companies in Other. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 91% of sector peers (real $). Modeled value above 91% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #66 of 465.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Ever/Body, Inc. | Series B | $64.2M | $430.2M | 2.73× |
| Financeware Holdings LLC | Series B | $59.7M | $413.0M | 2.62× |
| American Cricket Enterprises Inc. | Series B | $39.0M | $409.2M | 2.59× |
| Xlerate Ultimate Holdings, Lp | Series B | $62.2M | $405.9M | 2.57× |
| MDME Ultimate Holdings, LP | Series B | $39.9M | $395.4M | 2.51× |
| aXiomatic, LLC | Series B | $138.8M | $389.3M | 2.47× |
| Moov Financial, Inc. | Series B | $69.2M | $378.4M | 2.40× |
| NovaVision Holdings, LLC | Series B | $38.4M | $373.9M | 2.37× |
| Ttxa Ii 2022, Lp | Series B | $35.0M | $369.4M | 2.34× |
| Encamp, Inc. | Series B | $54.0M | $363.2M | 2.30× |
| JAF Communications Holdings, LLC | Series B | $36.8M | $358.7M | 2.27× |
| Enboarder Inc. | Series B | $39.7M | $357.0M | 2.26× |
| Trivela Pathway LP this company | Series B | $39.4M | $267.3M | 1.69× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series B | $39.4M | 2024-02-16 | $218.9M | $267.3M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Trivela Pathway LP is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Crayon, Inc. | Other | Series B | $39.1M | $293.9M | same sector · same stage |
| Ohalo Genetics, Inc. | Other | Series B | $40.0M | $278.2M | same sector · same stage |
| Reverb Holdings, Inc. | Other | Series B | $40.0M | $249.2M | same sector · same stage |
| TRAM Services Holdings, LLC | Other | Series B | $40.2M | $228.7M | same sector · same stage |
| Certain, Inc. | Other | Series B | $38.7M | $295.6M | same sector · same stage |
| Hastings Holding Corp. | Other | Series B | $40.6M | $263.6M | same sector · same stage |
| Rightscale Inc. | Other | Series B | $40.6M | $259.2M | same sector · same stage |
| Cogniac Corp | Other | Series B | $40.7M | $255.8M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Trivela Group UK LLC | Other | Series A | $37.7M | 79% |
| Reach Pathways L3C | Other | Seed | $4.4M | 77% |
| Journey Parent, LP | Other | Series C | $998.3M | 76% |
| Tristoria LLC | Other | Pre-Seed | $6.9M | 72% |
| TriFlo Cardiovascular Inc | Other | Series A | $208.2M | 72% |
| PathwaysGI, Inc. | Other Health Care | Pre-Seed | $2.9M | 72% |
| Triloma Financial Group LLC | Other | Series A | $95.9M | 71% |
| Trifecta Ecosystems, Inc. | Other Technology | Pre-Seed | $21.2M | 71% |
See where Trivela Pathway LP sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Trivela Pathway LP, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.